OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
(World News Austria)

OSE Immunotherapeutics SA , today announces the positive results of two preclinical studies evaluating FR104, an anti-antagonist antibody of CD28, a receptor which controls the activity of effector T lymphocytes. The first study, conducted in collaboration with the University of Oxford, was published in the JCI Insight . ......